CSPC Pharmaceutical Group Limited (HKG:1093)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 89.38B |
| Revenue (ttm) | 28.99B |
| Net Income (ttm) | 4.50B |
| Shares Out | 11.43B |
| EPS (ttm) | 0.39 |
| PE Ratio | 20.24 |
| Forward PE | 15.77 |
| Dividend | 0.26 (3.26%) |
| Ex-Dividend Date | Jun 4, 2025 |
| Volume | 151,643,570 |
| Average Volume | 275,383,943 |
| Open | 7.97 |
| Previous Close | 7.97 |
| Day's Range | 7.63 - 7.97 |
| 52-Week Range | 4.27 - 9.48 |
| Beta | 0.78 |
| RSI | 52.19 |
| Earnings Date | Aug 20, 2025 |
About CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma,... [Read more]
Financial Performance
In 2024, CSPC Pharmaceutical Group's revenue was 29.01 billion, a decrease of -7.76% compared to the previous year's 31.45 billion. Earnings were 4.33 billion, a decrease of -26.31%.
Financial numbers in CNY Financial StatementsNews
AstraZeneca Inks China AI Research Deal For Chronic Diseases
British drugmaker AstraZeneca unveiled on Friday an AI-assisted research partnership with Chinese counterpart CSPC Pharmaceuticals worth up to $5.3 billion to tackle chronic diseases.
AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion
On Friday, AstraZeneca Plc (NASDAQ: AZN) entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited . Per the agreement, AstraZeneca and CSPC agree to ...
AstraZeneca signs US$5 billion research deal with China’s CSPC
AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the Anglo-Swedish drugmaker said on Friday.
CSPC Pharma Pursues Licensing Deals After Lackluster Earnings
The Chinese drug giant revealed it was in talks with three parties to license its products for up to $5 billion in potential fees, a day after it delivered lackluster earnings Key Takeaways: The drug ...
Chinese biotech’s mega drug-licensing deals with multinationals surge
A potential multibillion-dollar deal unveiled on Friday by CSPC Pharmaceutical Group is the latest in a growing number of agreements by Chinese biotechnology firms to license development rights for in...
CSPC Pharmaceutical Group Limited goes ex dividend tomorrow
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
AstraZeneca (NASDAQ: AZN) announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(...
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 150 points on Monday. The Dow traded down 0.97% to 41,940.43 while the NASDAQ fell 0.89% to 17,976.85. T...
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday. The Dow traded down 0.49% to 42,146.78 while the NASDAQ fell 0.36% to 18,073.37. The S...
US Stocks Open Lower; Dow Tumbles Over 150 Points
U.S. stocks traded lower this morning, with the Dow Jones falling more than 150 points on Monday. Following the market opening Monday, the Dow traded down 0.38% to 42,192.55 while the NASDAQ fell 0.29...
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
On Monday, AstraZeneca plc (NASDAQ: AZN) entered into an exclusive license agreement with Hong Kong-based CSPC Pharmaceutical Group Ltd to advance the development of an early-stage, novel small-molec...